Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study

Haematologica

Volumn 88, Issue 4, 2003, Pages 445-453

  Oriol, Albert ^b   Ribera, Josep Maria ^a   Esteve, Jordi ^b   Sanz, Miguel Angel ^b   Brunet, Salut ^b   Garcia Boyero, Raimundo ^b   Fernández Abellán, Pascual ^b   Martí, Josep Maria ^b   Abella, Eugènia ^b   Sánchez Delgado, Magdalena ^b   Peñarrubia, Maria Jesús ^b   Besalduch, Joan ^b   Moreno, Maria José ^b   Borrego, Domingo ^b   Feliu, Evarist ^b   Ortega, Juan José ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

Burkitt's lymphoma leukemia; HIV infection; Intensive chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR CELL DESTRUCTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; FEMALE; HIV INFECTIONS; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037697771     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
2. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood 1992;80:2471-8.
3. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol 1996; 14:1252-61.
4. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94:3294-306.
5. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Society Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
6. Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo GS, Collini P, et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol 2002; 20:2783-8.
7. Soussain C, Patte C, Ostronoff M. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85:664-74.
8. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-34.
9. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996;87:495-508.
10. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-70.
11. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001;19:4014-22.
12. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
13. Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997;73:645-50.
14. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin's lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-12.
15. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-44.
16. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
17. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Br Med J 1999;319:23-4.
18. Eltom MA, Jemal A, Mbulaiteye SM, Devessa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in United States from 1973 to 1998. J Natl Cancer Inst 2002;94:1204-10.
19. Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001;15:2119-27.
20. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-15.
21. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91.
22. Ribera JM, Navarro JT, Oriol A, Lopez-Guillermo A, Sureda A, Abella E, et al. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS 2002; 16:1973-6.
23. Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-8.
24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
25. ISCN: an International System for Human Cytogenetic Nomenclature. Mittelman F, Ed. Karger, Basel; Switzerland, 1995.
26. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
27. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
28. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
29. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-6.
30. Fordyce EJ, Singh TP, Nash D, Gallagher B, Forlenza S. Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr 2002;30:111-8.
31. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. The AIDS Malignancy Consortium. J Clin Oncol 2001;19:2171-8.
32. Navarro JT, Ribera JM, Vaquero M, Pastor MC, Oriol A, Romeu J, et al. Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma. AIDS 2000;14:1460-1.
33. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94: 1492-9.
34. Wang ES, Strauss D, Quin J, Teruya-Feldstein L, Noy A. Intensive chemotherapy CODOX-M/IVAC compares favorably with other regimens for HIV positive and negative patients with Burkitt lymphoma. Blood 2000;1:96 Suppl 139a[abstract].
35. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264-74.